BI 1291583 for Bronchiectasis
Trial Summary
What is the purpose of this trial?
This study is open to adults with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants complete a daily diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.
Research Team
Eligibility Criteria
Adults with bronchiectasis who produce sputum and have had at least 2 flare-ups or 1 flare-up with significant symptoms can join. They must consent to the study, use effective birth control if applicable, and have a CT-confirmed diagnosis. Those on certain chronic treatments need at least one recent exacerbation.Inclusion Criteria
Treatment Details
Interventions
- BI 1291583 (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boehringer Ingelheim
Lead Sponsor